Impact of low-level pretransplant donor-specific antibodies detected by the Luminex platform on acute rejection and long-term graft survival

Table 2 Donor-specific antibodies against human leukocyte antigen class positivity and rejection episodes

Parameter	Mean DSA MFI
DSA Class I, n = 36 (46.2%)	3286.58 ± 4530.50; Range: 933-9994
DSA Class II, n = 35 (44.8%)	3207.47 ± 4219.00; Range: 1041-9383
DSA Class I and II, n = 7 (8.9%)	Class I = 3245.00 ± 2117.00; Range: 5515-6518
	Class II = 2101.00 ± 959.00; Range: 2336- 3610
In rejection (n = 8)
Class I, n = 2 (25.0%)	Median = 4994 (IQR = 3922-4994)
Class II, n = 6 (75.0%)	Median = 2718 (IQR = 1221-5173)
In no rejection (n = 63)
Class I, n = 34 (48.5%)	Median = 2481 (IQR = 1732-4136)
Class II, n = 29 (41.4%)	Median = 3088 (IQR = 1479- 5249)

DSA: Donor-specific antibodies; MFI: Mean fluorescence index; IQR: Interquartile range.